TUSTIN, CA--(Marketwire - July 05, 2012) -
Peregrine Pharmaceuticals, Inc. (NASDAQ:
PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that Steven King, president and chief executive officer, will present at the 2012 JMP Securities Healthcare Conference at the Peninsula Hotel in New York, NY on Thursday, July 12, 2012 at 9:30 AM Eastern Daylight Time.
Peregrine's presentation will be webcast live and available for replay until July 26, 2012 at: http://ir.peregrineinc.com/events.cfm
For more information about this conference, please visit: http://www.jmpg.com/jmpsecurities/about/conferences/
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.
